Neurocrine Biosciences

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$622,100
$590,200
$515,299
$515,200
Gross Profit
614,100
574,600
502,499
506,700
EBITDA
196,800
155,200
111,500
156,000
EBIT
190,300
147,900
105,300
150,300
Net Income
129,800
65,000
43,400
147,700
Net Change In Cash
622,100
590,200
515,299
515,200
Free Cash Flow
149,900
52,999
119,100
118,100
Cash
349,100
139,700
396,300
251,100
Basic Shares
104,300
103,900
103,600
102,300

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$1,887,100
$1,488,700
$1,133,500
$1,045,900
Gross Profit
1,847,400
1,465,500
1,119,200
1,035,800
EBITDA
416,100
264,600
218,700
336,100
EBIT
394,800
249,000
207,800
327,500
Net Income
249,700
154,500
89,600
407,300
Net Change In Cash
1,887,100
1,488,700
1,133,500
1,045,900
Cost of Revenue
-72,000
153,700
74,800
Free Cash Flow
361,600
322,900
233,100
217,600
Cash
251,100
262,900
340,800
801,000
Basic Shares
101,000
98,900
97,900
97,800

Earnings Calls

Quarter EPS
2024-09-30
$1.24
2024-06-30
$0.63
2024-03-31
$0.42
2023-12-31
$1.44